Carcinoma with Triphasic Differentiation Arising from Inverted Papilloma in Sinonasal Sinus: A Rare Case with Molecular Characterization

So-Woon Kim and Kiyong Na *

Abstract: Small cell neuroendocrine carcinoma (SNEC) is a rare subset of tumors in the sinonasal sinus. Combined tumors are exceedingly rare. Here, we describe a 65-year-old male with a mixed tumor of SNEC and sarcomatoid carcinoma arising in an inverted papilloma, containing squamous cell carcinoma in situ (SqCCis) in the sinonasal sinus. We evaluated the molecular characteristics of the two separate carcinoma components using next-generation sequencing. The patient presented with a nasal obstruction. Computed tomography showed a mass infiltrating the right ethmoid and maxillary sinuses. An excisional biopsy was performed. The tumor was found to have three morphologically distinct components. The first was SqCCis arising in an inverted papilloma, which was positive for cytokeratin and P40. The second consisted of nests of densely packed small round cells representing SNEC-positive neuroendocrine markers. The third was a solid sheet of anaplastic spindle cell proliferation, which was negative for the above markers. Oncogenic mutations such as \( \text{FBXW7} \), \( \text{TP53} \), and \( \text{EGFR} \) were detected in both SNEC and sarcomatoid carcinoma, and \( \text{MYCL} \) amplification was observed only in the SNEC component. This case highlights an extremely rare presentation of combined SNEC and sarcomatoid carcinoma arising from an inverted papilloma in the sinonasal sinus.

Keywords: small cell neuroendocrine carcinoma; sarcomatoid carcinoma; squamous cell carcinoma; sinonasal sinus; composite tumor

Tumors of the sinonasal tract are rare, representing approximately 3% of head and neck malignancies and approximately 0.3% of all malignant tumors [1]. The most frequent histologic subtype is squamous cell carcinoma (SqCC), followed by adenocarcinoma, melanoma, and olfactory neuroblastoma [1,2]. Small cell neuroendocrine carcinoma (SNEC) is a rare tumor in the head and neck region that occurs most frequently in the larynx, while sinonasal sinuses are exceedingly rare primary sites [3].

Only a small case series and case reports have been published regarding primary sinonasal tract SNEC [3]. In addition, only a few examples of combined tumor have been reported in the sinonasal tract. These consisted mainly of a combination of adenocarcinoma and neuroendocrine carcinoma, while cases of combined small cell and SqCC appear to be very rare [1,4]. Furthermore, the collision of three components (neuroendocrine cells, sarcomatous cells, and squamous cells) in a solid tumor is extremely rare, and no reports of combined tumors with these triphasic features have been reported in the literature [2].

Here, we describe the clinicopathological, immunohistochemical and molecular features of primary combined SNEC and sarcomatoid carcinoma arising from an inverted papilloma containing squamous cell carcinoma in situ (SqCCis) in the sinonasal sinus.

Next, we performed next-generation sequencing on each SNEC and the sarcomatoid carcinoma component to analyze the molecular heterogeneity of the tumor. As a result, oncogenic mutations, such as \( \text{FBXW7} \) (c.1972C>T, p. R658*), \( \text{TP53} \) (c.740A>T, p. N247I),
and EGFR (c.2319_2320insAACCCCCAC, p. D770_N771insNPH) were detected in both the SNEC and sarcomatoid carcinoma components. Of note, MYCL amplification was observed only in the SNEC component, a frequent oncogenic event in SNEC, supporting our diagnosis. [5]. FBXW7 is well known to be highly frequently mutated in SqCC, and a loss of TP53 and mutation of FBXW7 in SqCC are known to lead to resistance to standard chemotherapy [6,7]. Therefore, it seems that this heterogeneous tumor arises from a single SqCC component and generates SNEC through further molecular alterations. The final stage was T4bN0M1.

After the biopsy, the patient underwent radiation therapy of 70.2 Gy. However, six months after surgical resection and radiation therapy, follow-up brain CT showed new round masses abutting the superior falx cerebri, left parietal lobe, and both frontal lobes (Figure 1D). The patient died later that month.
best of our knowledge, there have been no cases of combined SNEC and sarcomatoid carcinoma diagnosed in the sinonasal sinus reported in the literature. Since it can affect the treatment plan of chemotherapy or radiation therapy depending on the components constituting the tumor, the need for accurate pathological diagnosis and technology is required. Our findings can help pathologists and clinicians make accurate histological diagnoses of combined SNEC and sarcomatoid carcinoma and plan an adequate treatment strategy for this rare tumor.

The stains used were hematoxylin and eosin stain (Figures 2 and 3) and the polymer method (Figure 3). The original magnifications were 40\times in Figure 2, 400\times in the inset of Figure 2, and 200\times in Figure 3.

![Image of histological sections](image)

**Figure 2.** Endoscopic excisional biopsy of the right nasal cavity mass was performed. The tumor was found to consist of three morphologically distinct components in the resected specimen. These components were partly clearly separated and partly strictly mixed. (A) The first component was SqCCis arising in inverted papilloma, which represented approximately 20% of the lesion. (B) The second component comprised of nests of closely packed, small round to atypical oval cells, with hyperchromatic nuclei, coarse chromatin, and scant pale eosinophilic cytoplasm. The tumor had karyorrhectic debris and mitotic activity. (C) This represented about 40% of the lesion. The third component consisted of a solid sheet of anaplastic spindle cells proliferation with prominent mitosis and multinucleated giant cells, which represented the remaining 40% of the lesion. (D) Of note, the focal area showed a tumor with admixed small round cell nests and anaplastic spindle cell elements overlying SqCCis. Asterisk, small round cell nest; arrow, spindle cell proliferation; right upper, squamous cell carcinoma in situ. The original magnifications were 40\times and 400\times in the inset.
Figure 3. To characterize each component, an immunohistochemical examination was performed. The results of the immunohistochemical studies are illustrated in Figure 3. (Left column) The three components clearly showed differences in their immunoprofiles. SqCCis was diffusely cytoplasmic positive for pan-cytokeratin (CK) and nuclear positive for P40, but negative for the neuroendocrine markers CD56, synaptophysin, and chromogranin. Conversely, the nests of atypical small cells were positive for CK with a perinuclear dot pattern and diffusely cytoplasmic positive for the neuroendocrine markers CD56, synaptophysin, and chromogranin. (Middle column) However, the nests were negative for P40. (Right column) The anaplastic spindle cell lesion was negative for all markers. Based on the histologic features and the results of the immunohistochemical studies, a diagnosis of combined SNEC and sarcomatoid carcinoma arising in an inverted papilloma was rendered. It is important to distinguish whether a spindle cell lesion is another sarcoma or a spindle cell variant of SqCC (sarcomatoid carcinoma). A diagnosis of sarcomatoid carcinoma can be considered if the existing conventional squamous cell carcinoma is mixed with the spindle cell lesion or if the SqCCis is present together [8,9]. In our case, because the spindle cell component coexisted with SqCCis, we diagnosed this component as sarcomatoid carcinoma rather than another sarcoma. The original magnifications were 200×.

Author Contributions: Conceptualization, S.-W.K. and K.N.; formal analysis: S.-W.K.; investigation, K.N.; writing—original draft preparation: S.-W.K. and K.N.; writing—review and editing, S.-W.K.
and K.N.; visualization, S.-W.K.; supervision, S.-W.K. and K.N.; project administration, S.-W.K. Both authors read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT, and Future Planning (NRF-2020R1G1A1003692).

**Institutional Review Board Statement:** The procedures were conducted in accordance with the Declaration of Helsinki. This study (project identification code: 2020-03-081, date of approval: 21 March 2020) was reviewed and approved by the Institutional Review Board of Kyung Hee University Hospital (Seoul, Korea).

**Informed Consent Statement:** All subjects provided informed consent for inclusion before they participated in the study.

**Data Availability Statement:** The data presented in this study are available upon request from the corresponding author. The data are not publicly available because of privacy and ethical restrictions.

**Conflicts of Interest:** The authors declare no conflict of interest regarding this study.

**References**

1. Wu, S.H.; Zhang, B.Z.; Han, L. Collision tumor of squamous cell carcinoma and neuroendocrine carcinoma in the head and neck: A case report. *World J. Clin. Cases* **2020**, *8*, 2610–2616. [CrossRef] [PubMed]
2. Huang, S.F.; Chuang, W.Y.; Cheng, S.D.; Hsin, L.J.; Lee, L.Y.; Kao, H.K. A colliding maxillary sinus cancer of adenosquamous carcinoma and small cell neuroendocrine carcinoma—a case report with EGFR copy number analysis. *World J. Surg. Oncol.* **2010**, *8*, 92. [CrossRef] [PubMed]
3. Bell, D. Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma. *Head Neck Pathol.* **2018**, *12*, 22–30. [CrossRef] [PubMed]
4. Franchi, A.; Rocchetta, D.; Palomba, A.; Degli Innocenti, D.R.; Castiglione, F.; Spinelli, G. Primary combined neuroendocrine and squamous cell carcinoma of the maxillary sinus: Report of a case with immunohistochemical and molecular characterization. *Head Neck Pathol.* **2015**, *9*, 107–113. [CrossRef] [PubMed]
5. Mollaoglu, G.; Guthrie, M.R.; Böhm, S.; Brägelmann, J.; Can, I.; Ballieu, P.M.; Marx, A.; George, J.; Heinen, C.; Chalishazar, M.D.; et al. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. *Cancer Cell* **2017**, *31*, 270–285. [CrossRef]
6. Yeh, C.-H.; Bellon, M.; Nicot, C. FBXW7: A critical tumor suppressor of human cancers. *Mol. Cancer* **2018**, *17*, 115. [CrossRef]
7. Sailo, B.L.; Banik, K.; Girisa, S.; Bordoloi, D.; Fan, L.; Halim, C.E.; Wang, H.; Kumar, A.P.; Zheng, D.; Mao, X.; et al. FBXW7 in Cancer: What Has Been Unraveled Thus Far? *Cancers* **2019**, *11*, 246. [CrossRef]
8. Mahajan, A.; Mohanty, S.; Ghosh, S.; Urs, A.B.; Khurana, N.; Gupta, S. Sarcomatoid Carcinoma of the Oral Cavity: A Diagnostic Dilemma. *Case Rep. Dent.* **2017**, *2017*, 7495695. [CrossRef] [PubMed]
9. Choi, H.-R.; Sturgis, E.M.; Rosenthal, D.I.; Luna, M.A.; Batsakis, J.G.; El-Naggar, A.K. Sarcomatoid Carcinoma of the Head and Neck: Molecular Evidence for Evolution and Progression From Conventional Squamous Cell Carcinomas. *Am. J. Surg. Pathol.* **2003**, *27*, 1216–1220. [CrossRef] [PubMed]